CLINICAL_TRIALS trial_result · 2024-10-23

Clinical Trial Update: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries [Phase 2]

Phase 2 trial of NEXAGON for corneal persistent epithelial defects following severe ocular injuries has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Glaukos Corporation | Conditions: Corneal Persistent Epithelial Defect | Phase 2 | Status: TERMINATED | Results posted: 2024-10-23